Dr. Francisco A. Kerdel attended the St. Thomas Hospital Medical School, London University in London, England. He completed his dermatology residency at Harvard Medical School in Boston, MA, where he was chief resident during the year 1983-1984. He completed fellowships at Guy’s Hospital, London, England and New York University School of Medicine, New York, NY.
He is the former Director of Dermatology Inpatient Unit at the University of Miami Hospital and former Professor of Dermatology at the University of Miami. Dr. Kerdel is a Past President of the International Society of Dermatology and the treasurer of the Foundation for International Dermatologic Education. He is currently a clinical professor at Florida International University, where he is also the Vice Chairman of the Department of Dermatology. He is also the Medical Director of Dermatology at Larkin Community Hospital. Dr. Kerdel’s society memberships include the American Academy of Dermatology, Society for Investigative Dermatology, American Dermatological Association, Noah Worcester Dermatological Society and Miami Society of Dermatology. Dr. Kerdel has been chosen to be an Honorary Member of the Venezuelan, Argentinean and Chilean Societies of Dermatology and a corresponding member of the Venezuelan Academy of Medicine.
He has authored over 202 scientific articles, 37 books and book chapters. As an invited speaker, Dr. Kerdel has spoken at national meetings and at international meetings worldwide. He has been a visiting professor in the United States, Japan, Portugal, Italy, Australia, Argentina, Brazil, Chile, Spain, Paraguay, United Kingdom, Venezuela, Colombia, Uruguay and Mexico.
Medical Treatments in Hidradenitis Suppurativa (H/S)
Physicians need to stay current on treatments for this chronic skin disease. This disease can cause chronic pain and could lead to self-consciousness, social isolation and depression for the patient.
- Understand hidradenitis suppurativa as a disease
- Use of biologics in hidradenitis suppurativa
- Possible new therapies in hidradenitis suppurativa
- New advances in dermatologic treatment
- Advances in medical knowledge
- Availability of new medication(s) or indication(s)
- Infliximab: Journal of American Academy of Dermatology, 2010;62:205.
- Adalimumab, New England Journal of Medicine, 2016;375:422.
Core Competencies: 2, 3, 6
Disclosures: Speaker: Centocor, Abbott, Amgen, Gsai, Astellas, Wyeth; Investigator: Novartis, Merck; Off-Label: Biologics and PDE4-Inhibitors in Hidradenitis Suppurativa